Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

63.64
-0.1100-0.17%
Pre-market: 64.180.5402+0.85%08:17 EDT
Volume:7.06M
Turnover:448.25M
Market Cap:129.56B
PE:14.01
High:64.20
Open:64.15
Low:63.27
Close:63.75
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.05
T/O Rate:0.35%
Dividend:2.51
Dividend Rate:3.94%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.80
PE(LYR):18.39

Loading ...

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First Celmod Therapy Zenbexus™, in Combination with Daratumumab and Hyaluronidase-Fihj and Dexamethasone (Zdd) for Patients with Multiple Myeloma, as Early as First Relapse

THOMSON REUTERS
·
Aug 14

Bristol-Myers Squibb - Zenbexus Available Only Through Restricted Zenbexus Rems Program

THOMSON REUTERS
·
Aug 14

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

US FDA Approves Bristol Myers' Blood Cancer Treatment

Reuters
·
Aug 14

FDA Grants Accelerated Approval to Iberdomide with Daratumumab and Hyaluronidase-Fihj and Dexamethasone for Multiple Myeloma

THOMSON REUTERS
·
Aug 14

Cytokinetics - Files Complaint Against Bristol-Myers Squibb and Myokardia - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics - Demands Trial by Jury on All Triable Issues - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics Sues Bristol Myers, MyoKardia Seeking Ruling on Myqorzo Patent Dispute

Reuters
·
Aug 13

Atrium Gets $15M in Latest Milestone Payment from Bristol Myers Squibb

Dow Jones
·
Aug 13

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

THOMSON REUTERS
·
Aug 13

Atrium Therapeutics - Eligible for up to $1.35 Bln R&D Milestones, $825 Mln Commercial Milestones, Tiered Royalties

THOMSON REUTERS
·
Aug 13

Atrium Therapeutics - Bristol Myers Squibb to Fund All Future Development and Commercialization Activities

THOMSON REUTERS
·
Aug 13

Switzerland's PolyPeptide H1 Revenue Rises on Stronger Metabolic Therapeutics Demand

Reuters
·
Aug 13

Why Bristol Myers Squibb (BMY) Is Back In The Spotlight

Simply Wall St.
·
Aug 13

BMY Expands Melanoma Immunotherapy Footprint With New Phase 4 Trial in India

TIPRANKS
·
Aug 13

Huang's $500 Billion Financing Plan Splits Markets: Asset Managers Rally as Tech Stocks Slide for Second Day

Deep News
·
Aug 12

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Aug 12

Savara Q2 Loss Widens as Operating Expenses Rise

Reuters
·
Aug 12

Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports

TIPRANKS
·
Aug 12

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 11